Baxter International (NYSE:BAX) Issues Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Baxter International (NYSE:BAX) issued its earnings results on Thursday. The medical instruments supplier reported $0.58 EPS for the quarter, beating the consensus estimate of $0.52 by $0.06, Zacks reports. Baxter International had a return on equity of 18.30% and a net margin of 0.77%. Baxter International updated its FY 2025 guidance to 2.450-2.550 EPS and its Q1 2025 guidance to 0.470-0.500 EPS.

Baxter International Stock Performance

Baxter International stock traded up $2.64 during midday trading on Thursday, hitting $33.46. The stock had a trading volume of 4,080,862 shares, compared to its average volume of 4,643,930. Baxter International has a 52-week low of $28.33 and a 52-week high of $44.01. The company has a market capitalization of $17.08 billion, a PE ratio of 167.21, a P/E/G ratio of 9.95 and a beta of 0.61. The firm’s fifty day moving average is $30.52 and its two-hundred day moving average is $34.15. The company has a current ratio of 1.43, a quick ratio of 1.09 and a debt-to-equity ratio of 1.31.

Baxter International Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 1st. Investors of record on Friday, February 28th will be paid a dividend of $0.17 per share. The ex-dividend date is Friday, February 28th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 2.03%. Baxter International’s dividend payout ratio (DPR) is presently 340.02%.

Wall Street Analysts Forecast Growth

BAX has been the subject of several research analyst reports. Citigroup reduced their price objective on Baxter International from $37.00 to $35.00 and set a “neutral” rating for the company in a report on Wednesday, December 11th. Stifel Nicolaus decreased their price objective on shares of Baxter International from $46.00 to $38.00 and set a “buy” rating for the company in a report on Monday, November 11th. Barclays assumed coverage on shares of Baxter International in a research report on Thursday. They issued an “overweight” rating and a $39.00 target price for the company. Finally, StockNews.com cut Baxter International from a “buy” rating to a “hold” rating in a report on Monday, November 11th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $39.40.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.